Concepedia

David Michelson

DM

Statistics

Publications

58

Citations

7.6K

H-Index

39

Active since

1994

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Eli Lilly (United States)

National Institute of Mental Health

Henry Ford Hospital

University of Pennsylvania

David Michelson is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Publications per year

1994–2021

58

Publications

58

Atomoxetine in the Treatment of Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Dose-Response Study

David Michelson, Douglas E. Faries, Joachim Wernicke et al. · PEDIATRICS · 2001 · 669 citations

Medicine, Pharmacology, Pharmacotherapy +17

Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease

Michael Egan, James Kost, Tiffini Voss et al. · New England Journal of Medicine · 2019 · 548 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Hypothalamic–pituitary–adrenal axis perturbations in patients with fibromyalgia

Leslie J. Crofford, Stanley R. Pillemer, Konstantine T. Kalogeras et al. · Arthritis & Rheumatism · 1994 · 514 citations

Medicine, Endocrinology, Physiology +17

Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial

David Michelson, Ellen Snyder, Erin M. Paradis et al. · The Lancet Neurology · 2014 · 509 citations

Medicine, Pharmacology, Pharmacotherapy +12

Bone Mineral Density in Women with Depression

David Michelson, Constantine A. Stratakis, Lauren Hill et al. · New England Journal of Medicine · 1996 · 469 citations · Full text

Medicine, Endocrinology, Psychiatry +17

1–5 of 58